Navigation Links
Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share
Date:12/10/2010

nsaction for $5.50 per share (the "Revised Offer") provided that Cypress commences exclusive negotiations with V&O Acquisition no later than Friday, December 10, 2010 and enters into a definitive merger agreement no later than Sunday, December 12, 2010.  V&O Acquisition's current tender offer is scheduled to expire on Friday, December 10, 2010.  To facilitate discussions, V&O Acquisition will be extending its existing tender offer for an additional five (5) business days, but reserves the right to terminate the tender offer at any time.

As of the date hereof, affiliates of Royalty Pharma Finance Trust ("Royalty Pharma") have indicated that they are prepared to invest approximately $196 million in cash in the equity of V&O Acquisition to enable V&O Acquisition to pay the amount payable to stockholders of Cypress pursuant to the Revised Offer.  Royalty Pharma's financing is not subject to due diligence or any other material condition.  However, Royalty Pharma has advised Ramius that it reserves the right to withdraw this financing arrangement if Cypress has not commenced exclusive negotiations with V&O Acquisition by midnight on Friday, December 10, 2010 and has not entered into a definitive merger agreement by midnight on Sunday, December 12, 2010.

V&O Acquisition believes that, as a result of its pending tender offer, it is able to acquire Cypress and pay the stockholders of Cypress the full value of their shares more quickly than any other potential bidder.  V&O Acquisition has completed all required due diligence and has sufficient funds to promptly close the tender offer.  

V&O Acquisition is willing to enter into a merger agreement giving effect to the Revised Offer, which is of significant value and brings immediate certainty to Cypress and its stockholders.  The terms would include the following:

  1. All cash offer of $5.50 per share.<
    '/>"/>

SOURCE Ramius LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cypress Denies Ramius Legal Right to Stockholder List Materials
2. UC San Diego Offers New Certificate for Clinical Trials Administration in Latin America
3. U of C scientist offers better ways to engineer Earths climate to prevent dangerous global warming
4. Emerson Ecologics Exclusively Offers EcoNugenics ProstaCaid
5. New paper offers breakthrough on blinking molecules phenomenon
6. Promega Now Offers Complete Solution for Profiling Kinase Inhibitor Compounds Against the Human Kinome
7. Research from Rensselaer Polytechnic Institute professor offers clues to Alzheimers disease
8. Carl Zeiss Offers Online Promotions &#8211; Discounts on Stereomicroscopy and Converting to 3D Imaging
9. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
10. Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists
11. Michael Youssef Offers Insight into the Muslim Perspective on Oil and the World Economy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Indianapolis, IN (PRWEB) December 17, 2014 ... for Laboratory Excellence following its most recent COLA ... Accreditation by COLA, a national healthcare accreditation organization. ... rigid standards of quality in day-to-day operations, demonstrate ... and pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... Calif. , Dec. 17, 2014 ... a Phase 2 study evaluating the investigational oral ... of patients with severe, chronic itch who are ... of care, including topical steroids and antihistamines. ... change in Visual Analog Scale (VAS) itch score ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , ... BCLI ), a leading developer of adult ... wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a ... Office of the Chief Scientist (OCS).  This ... receipt of grant support from the Office of the ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... SAN FRANCISCO, Calif., March 5 Poniard Pharmaceuticals, ... company focused on innovative oncology therapies, today announced ... discuss the Company,s fourth quarter and year-end financial ... development activities for picoplatin, the Company,s lead product ...
... Proteon Therapeutics, Inc., announced today that it has successfully ... by MPM Capital on behalf of the MPM Bio ... the initiation of a Phase 1/2 human clinical study ... stage renal disease undergoing surgery for arteriovenous fistula (AVF) ...
... - Proceeds to Facilitate Clinical Development of ... a pioneer in the development of innovative conjugated,vaccines, today ... million, EUR17 million) Series B financing. The round was ... Ventures and,Sofinnova Partners, expressed their commitment to the future ...
Cached Biology Technology:Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12 2Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company 2GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners 2
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San Diego ... that provides the connective tissue that enhances care coordination ... to easily share client-level information; earned a second $1 ... to organizations serving seniors aging in community and; will ... on December 11 th 4-6p. CIE ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... In a multifaceted study involving the Kuna Indians ... pinpointed a chemical compound that is, in part, ... and some chocolate products. , The researchers, who ... Heinrich-Heine University of Duesseldorf, Germany; and Harvard Medical ...
... using a toothbrush, the Norwegians found one using a drill. The ... Sea, at an entire 2256 metres below the seabed. It had ... the North Sea wasn't a sea at all, but an enormous ... of the old dinosaur now see the light of day again, ...
... against not only multi drug-resistant forms of the disease but ... stage of infection as well. Researchers report their results ... class of which this compound is the lead has a ... used to treat tuberculosis. We have identified no cross ...
Cached Biology News:Heart-healthy compound in chocolate identified 2Experimental TB drug effective against resistant and latent mycobacterium tuberculosis 2
...
...
with GlutaMAXIL-glutamine...
... GOAT ANTI-MOUSE IgG+IgA+IgM (H+L) ... with highly purified horseradish ... antibody has been absorbed ... fetal bovine, horse, goat, ...
Biology Products: